Molecular Target	Entrez Gene Name	Enterez Gene Id	Drug name	Other drug name	Pubchem name	CID	SID	Interaction type	Mode of action	Clinical Trial ID(s)	Detail	Phase	Include this entry?	Comments
ALK1 ligands (TGFbeta family)	ACVRL1	94	Dalantercept	ACE-041, ALK1-Fc Fusion Protein ACE-041	Dalantercept	N/A	160693095	inhibitor	ALK1 inhibitor	NCT01720173	Recurrent epithelial ovarian cancer A Phase II Evaluation of Dalantercept (NSC #75172, IND #116598), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
AKT1-3	AKT1	207	GSK2141795	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01138085	Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2)	I	1	
AKT1-3	AKT1	207	AZD5363	Akt inhibitor AZD5363	AZD5363	25227436	N/A	inhibitor	Akt inhibitor	NCT01226316	Advanced Solid Tumors; Ovarian Cancer; AKT1 or PIK3CA mutant cancers A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.	I	1	
AKT1-3	AKT1	207	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01245205	Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer	I	1	
AKT1-3	AKT1	207	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01295632	Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer	I	1	
AKT1-3	AKT1	207	ARQ092	N/A	N/A	N/A	N/A	inhibitor	pan-AKT inhibitor	NCT01473095	Advanced solid tumors Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors	I	1	
AKT1-3	AKT1	207	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01480154	Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis	I	1	
AKT1-3	AKT1	207	GSK2141795	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01902173	BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer	I	1	
AKT1-3	AKT1	207	SAR260301	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01673737	Advanced Solid Tumors A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma	I/Ib	1	
AKT1-3	AKT1	207	Afuresertib	GSK2110183	Afuresertib hydrochloride	46843056	N/A	inhibitor	Akt inhibitor	NCT01653912	Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer	I/II	1	
AKT1-3	AKT1	207	Triciribine	API-2, triciribine phosphate, tricyclic nucleoside, tricycloside phosphate	Triciribine	65399	N/A	inhibitor	Akt inhibitor	NCT01690468	recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research	I/II	1	
AKT1-3	AKT1	207	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01235897	Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab	Ib	1	
AKT1-3	AKT1	207	GDC-0068	Akt Inhibitor GDC-0068	GDC-0068	24788740	N/A	inhibitor	Akt inhibitor	NCT01562275	Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors	Ib	1	
AKT1-3	AKT2	208	GSK2141795	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01138085	Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2)	I	1	
AKT1-3	AKT2	208	AZD5363	Akt inhibitor AZD5363	AZD5363	25227436	N/A	inhibitor	Akt inhibitor	NCT01226316	Advanced Solid Tumors; Ovarian Cancer; AKT1 or PIK3CA mutant cancers A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.	I	1	
AKT1-3	AKT2	208	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01245205	Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer	I	1	Lapatinib is approved for breast cancer
AKT1-3	AKT2	208	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01295632	Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer	I	1	
AKT1-3	AKT2	208	ARQ092	N/A	N/A	N/A	N/A	inhibitor	pan-AKT inhibitor	NCT01473095	Advanced solid tumors Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors	I	1	
AKT1-3	AKT2	208	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01480154	Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis	I	1	
AKT1-3	AKT2	208	GSK2141795	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01902173	BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer	I	1	
AKT1-3	AKT2	208	SAR260301	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01673737	Advanced Solid Tumors A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma	I/Ib	1	
AKT1-3	AKT2	208	Afuresertib	GSK2110183	Afuresertib hydrochloride	46843056	N/A	inhibitor	Akt inhibitor	NCT01653912	Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer	I/II	1	
AKT1-3	AKT2	208	Triciribine	API-2, triciribine phosphate, tricyclic nucleoside, tricycloside phosphate	Triciribine	65399	N/A	inhibitor	Akt inhibitor	NCT01690468	recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research	I/II	1	
AKT1-3	AKT2	208	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01235897	Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab	Ib	1	
AKT1-3	AKT2	208	GDC-0068	Akt Inhibitor GDC-0068	GDC-0068	24788740	N/A	inhibitor	Akt inhibitor	NCT01562275	Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors	Ib	1	
AKT1-3	AKT3	10000	GSK2141795	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01138085	Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2)	I	1	
AKT1-3	AKT3	10000	AZD5363	Akt inhibitor AZD5363	AZD5363	25227436	N/A	inhibitor	Akt inhibitor	NCT01226316	Advanced Solid Tumors; Ovarian Cancer; AKT1 or PIK3CA mutant cancers A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.	I	1	
AKT1-3	AKT3	10000	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01245205	Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer	I	1	
AKT1-3	AKT3	10000	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01295632	Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer	I	1	
AKT1-3	AKT3	10000	ARQ092	N/A	N/A	N/A	N/A	inhibitor	pan-AKT inhibitor	NCT01473095	Advanced solid tumors Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors	I	1	
AKT1-3	AKT3	10000	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01480154	Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis	I	1	
AKT1-3	AKT3	10000	GSK2141795	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01902173	BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer	I	1	
AKT1-3	AKT3	10000	SAR260301	N/A	N/A	N/A	N/A	inhibitor	Akt inhibitor	NCT01673737	Advanced Solid Tumors A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma	I/Ib	1	
AKT1-3	AKT3	10000	Afuresertib	GSK2110183	Afuresertib hydrochloride	46843056	N/A	inhibitor	Akt inhibitor	NCT01653912	Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer	I/II	1	
AKT1-3	AKT3	10000	Triciribine	API-2, triciribine phosphate, tricyclic nucleoside, tricycloside phosphate	Triciribine	65399	N/A	inhibitor	Akt inhibitor	NCT01690468	recurrent or persistent, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma Leveraging a Clinico-Genomic Database to Match Patients to a Trial of Triciribine and Carboplatin: Changing Paradigms in Ovarian Cancer Clinical Research	I/II	1	
AKT1-3	AKT3	10000	MK2206	Akt Inhibitor MK2206	MK2206	46930998	N/A	inhibitor	Akt inhibitor	NCT01235897	Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab	Ib	1	
AKT1-3	AKT3	10000	GDC-0068	Akt Inhibitor GDC-0068	GDC-0068	24788740	N/A	inhibitor	Akt inhibitor	NCT01562275	Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors	Ib	1	
Ang1	ANGPT1	284	Trebaninib	AMG 386	Trebaninib	N/A	160671634	inhibitor	Tie2R inhibitor	NCT01281254	Recurrent ovarian cancer A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	III	1	
Ang1	ANGPT1	284	Trebaninib	AMG 386	Trebaninib	N/A	160671634	inhibitor	Tie2R inhibitor	NCT01493505	Newly diagnosed stage III-IV ovarian epithelial cancer A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	III	1	Carboplatin is approved for ovarian cancer
Ang2	ANGPT2	285	MED13617	anti-Angiopoietin 2 mab	N/A	N/A	N/A	antagonist	Angiopoietin 2 antagonist	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
Gamma-secretase	APH1A	51107	BMS-906024	N/A	UNII-DRL23N424R	66550890	N/A	inhibitor	Gamma-secretase inhibitor	NCT01292655	Advanced cancer Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors	I	1	
Gamma-secretase	APH1A	51107	MK0752	N/A	MK-0752	9803433	N/A	inhibitor	Notch signaling pathway inhibitor	NCT01295632	Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer	I	1	
Gamma-secretase	APH1B	83464	BMS-906024	N/A	UNII-DRL23N424R	66550890	N/A	inhibitor	Gamma-secretase inhibitor	NCT01292655	Advanced cancer Study to Evaluate the Safety and Tolerability of Weekly IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors	I	1	
Gamma-secretase	APH1B	83464	MK0752	N/A	MK-0752	9803433	N/A	inhibitor	Notch signaling pathway inhibitor	NCT01295632	Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer	I	1	
Aurora A Kinase	AURKA	6790	AMG 900	Aurora Kinase Inhibitor AMG 900	AMG900	24856041	N/A	inhibitor	pan-Aurora kinase inhibitor	NCT00858377	Advanced solid tumors A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors	I	1	
Aurora A kinase	AURKA	6790	Alisertib	MLN8237	ALISERTIB SODIUM	56843791	N/A	inhibitor	Aurora A kinase inhibitor	NCT01094288	Advanced Solid Tumors A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen	I	1	
Aurora A Kinase	AURKA	6790	ABT-384	N/A	N/A	N/A	N/A	inhibitor	pan-Aurora Kinase inhibitor (B/C >A)	NCT01110486	Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors	I	1	
Aurora A kinase	AURKA	6790	Alisertib	MLN8237	ALISERTIB SODIUM	56843791	N/A	inhibitor	Aurora A kinase inhibitor	NCT01639911	Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
Aurora A kinase	AURKA	6790	Alisertib	MLN8237	ALISERTIB SODIUM	56843791	N/A	inhibitor	Aurora A kinase inhibitor	NCT01639911	Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
Aurora A kinase	AURKA	6790	Alisertib	MLN8237	ALISERTIB SODIUM	56843791	N/A	inhibitor	Aurora A kinase inhibitor	NCT01091428	Recurrent epithelial ovarian carcinoma MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer	I/II	1	
Aurora A kinase	AURKA	6790	Alisertib	MLN8237	ALISERTIB SODIUM	56843791	N/A	inhibitor	Aurora A kinase inhibitor	NCT01613261	Advanced Solid Tumors A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies	Ib	1	
Aurora A kinase	AURKA	6790	Alisertib	MLN8237	ALISERTIB SODIUM	56843791	N/A	inhibitor	Aurora A kinase inhibitor	NCT01653028	Advanced ovarian carcinosarcoma Phase II Study of MLN8237 in Advanced / Metastatic Sarcoma	II	1	'Aurora A kinase' is not found in Entrez by this name but it is there -> AURKA
Aurora A kinase	AURKA	6790	ENMD-2076	N/A	ENMD-2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
Aurora B Kinase	AURKB	9212	AMG 900	Aurora Kinase Inhibitor AMG 900	AMG900	24856041	N/A	inhibitor	pan-Aurora kinase inhibitor	NCT00858377	Advanced solid tumors A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors	I	1	
Aurora B Kinase	AURKB	9212	ABT-384	N/A	N/A	N/A	N/A	inhibitor	pan-Aurora Kinase inhibitor (B/C >A)	NCT01110486	Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors	I	1	
Aurora C Kinase	AURKC	6795	AMG 900	Aurora Kinase Inhibitor AMG 900	AMG900	24856041	N/A	inhibitor	pan-Aurora kinase inhibitor	NCT00858377	Advanced solid tumors A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors	I	1	
Aurora C Kinase	AURKC	6795	ABT-384	N/A	N/A	N/A	N/A	inhibitor	pan-Aurora Kinase inhibitor (B/C >A)	NCT01110486	Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors	I	1	
Bcl2	BCL2	596	Paclitaxel Albumin-Stabilized Nanoparticle Formulation	ABI-007, Abraxane, nab-paclitaxel	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00313599	Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors	I	1	Paclitaxel nanoparticle
Bcl2	BCL2	596	Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation	ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00825201	Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity	I	1	Albumin nanoparticle
Bcl2	BCL2	596	Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation	ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00825201	Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity	I	1	Albumin-paclitaxel nanoparticle
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	quadraple therapy
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01209195	Locally advanced/metastatic or recurrent epithelial ovarian cancer A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01256268	Metastatic or Recurrent Ovarian Cancer elegible for carbo-taxol treatment Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01366144	Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01411410	Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01649336	Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01688791	Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01778803	Adv or refractory ovarian cancer A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01831089	Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors	I	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00976183	Stage III/IV ovarian cancer cancer, not have received chemotherapy yet Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma	I/II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01091428	Recurrent epithelial ovarian carcinoma MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer	I/II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01650376	Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients	I/II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01653912	Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer	I/II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01696032	Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer	I/II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01711970	Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mllerian Cancer	I/II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01235897	Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab	Ib	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00585052	Platinum-refractory or -resistant ovarian cancer A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer	II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01097746	Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer	II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01196429	Newly diagnosed stage III or stage IV clear cell ovarian cancer. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer	II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01357161	Platinum-sensitive p53 mutant ovarian cancer A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer	II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01616303	Newly diagnosed advanced ovarian cancer Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma	II	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
Bcl2	BCL2	596	Paclitaxel, Paclitaxel Poliglumex	Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00108745	Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer	III	1	
Bcl2	BCL2	596	Paclitaxel, Paclitaxel Poliglumex	Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00108745	Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer	III	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00565851	Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	III	1	Bevacizumab is already approved for ovarian cancer
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00954174	Persistent or recurrent ovarian cancer Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer	III	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01167712	Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	III	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01239732	Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma	III	1	Bevacizumab is already approved for ovarian cancer
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01493505	Newly diagnosed stage III-IV ovarian epithelial cancer A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	III	1	
Bcl2	BCL2	596	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	1	
IAP inhibitor	BIRC2	329	Birinapant	Smac Mimetic TL32711, TL32711	Birinapant	49836020	N/A	antagonist	inhibitor of apoptosis (IAP) antagonist	NCT01681368	Platinum Resistant or Refractory Epithelial Ovarian Cancer Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal	II	1	
ALK1 ligands (TGFbeta family)	BMP10	27302	Dalantercept	ACE-041, ALK1-Fc Fusion Protein ACE-041	Dalantercept	N/A	160693095	inhibitor	ALK1 inhibitor	NCT01720173	Recurrent epithelial ovarian cancer A Phase II Evaluation of Dalantercept (NSC #75172, IND #116598), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
RAF	BRAF	673	Sorafenib	BAY 43-9006, BAY 43-9006 tosylate salt, Nexavar	Sorafenib	216239	N/A	inhibitors	RAF, VEGFR2, and PDGFR-beta inhibitors	NCT01303341	Advanced solid tumors A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma	I	1	
BRAF	BRAF	673	Vemurafenib	PLX4032, RO5185426, Zelboraf	Vemurafenib	23252090	N/A	inhibitor	BRAF kinase inhibitor	NCT01596140	B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer	I	1	
BRAF	BRAF	673	Dabrafenib	BRAF inhibitor GSK2118436, GSK2118436, Tafinlar	GSK 2118436	44516822	N/A	inhibitor	BRAF kinase inhibitor	NCT01902173	BRAF V600 mutant metastatic cancer Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With the BRAF Inhibitor Dabrafenib in Patients With BRAF Mutant Cancer	I	1	
RAF	BRAF	673	LGX818	Raf Kinase Inhibitor LGX818	N/A	N/A	N/A	inhibitor	RAF inhibitor	NCT01543698	Solid Tumors Harboring a BRAF V600 Mutation A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	Ib/II	1	
c-Met	c-Met	4233	EMD 1214063	N/A	N/A	N/A	N/A	inhibitor	c-Met kinase inhibitor	NCT01014936	Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1214063 Under Two Different Regimens in Subjects With Advanced Solid Tumors	I	1	
c-Met	c-Met	4233	AMG 337	N/A	N/A	N/A	N/A	inhibitor	c-Met inhibitor	NCT01253707	Advanced solid tumors A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors	I	1	
c-Met	c-Met	4233	INC280	N/A	N/A	N/A	N/A	inhibitor	c-Met kinase inhibitor	NCT01324479	c-Met dependent advanced solid tumors A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors	I	1	
c-Met	c-Met	4233	Cabozantanib	Cabozantinib, Cometriq	cabozantinib	25102847	N/A	inhibitor	RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
Caspases	CASP3	836	Idronoxil	Phenoxodiol	phenoxodiol	219100	N/A	inhibitor	Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	1	
CD27	CD27	939	CDX-1127	Anti-CD27 Monoclonal Antibody CDX-1127	N/A	N/A	N/A	immunostimulator	immunostimulator	NCT01460134	Recurrent or refractory ovarian cancer A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors	I	1	
UNK Cancer Stem Cell antigen	CD276	80381	MGA271	mab MGA271	N/A	N/A	N/A	antigen	immunological response against cancer antigen	NCT01391143	B7-H3 over-expressing adv cancer A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer	I	1	
CDK1, 2, 3, 4, 7, 9	CDK1	983	BAY 1000394	pan-CDK Inhibitor BAY1000394	N/A	N/A	N/A	inhibitor	pan-CDK inhibitor	NCT01188252	Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies	I	1	
CDK1, 2, 5, 9	CDK1	983	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK1, 2, 5, 9	CDK1	983	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK1, 2, 3, 4, 7, 9	CDK2	1017	BAY 1000394	pan-CDK Inhibitor BAY1000394	N/A	N/A	N/A	inhibitor	pan-CDK inhibitor	NCT01188252	Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies	I	1	
CDK1, 2, 5, 9	CDK2	1017	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK1, 2, 5, 9	CDK2	1017	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK1, 2, 3, 4, 7, 9	CDK3	1018	BAY 1000394	pan-CDK Inhibitor BAY1000394	N/A	N/A	N/A	inhibitor	pan-CDK inhibitor	NCT01188252	Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies	I	1	
CDK1, 2, 3, 4, 7, 9	CDK4	1019	BAY 1000394	pan-CDK Inhibitor BAY1000394	N/A	N/A	N/A	inhibitor	pan-CDK inhibitor	NCT01188252	Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies	I	1	
CDK4/6	CDK4	1019	LEE011	CDK4/6 Inhibitor LEE011	N/A	N/A	N/A	inhibitor	CDK4/6 inhibitor	NCT01237236	Advanced cancer A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma	I	1	
CDK4/6	CDK4	1019	LY2835219	CDK4/6 Dual Inhibitor LY2835219	CS1229	71576678	N/A	inhibitor	CDK4/6 inhibitor	NCT01394016	Advanced Cancer A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer	I	1	
CDK4/6	CDK4	1019	Palbociblib	PD0332991	CID 5330286	5330286	N/A	inhibitor	CDK4/6 inhibitor	NCT01037790	Recurrent Ovarian Cancer Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	II	1	
CDK4/6	CDK4	1019	Palbociblib	PD0332991	CID 5330286	5330286	N/A	inhibitor	CDK4/6 inhibitor	NCT01536743	Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression	II	1	
CDK1, 2, 5, 9	CDK5	1020	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK1, 2, 5, 9	CDK5	1020	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK4/6	CDK6	1021	LEE011	CDK4/6 Inhibitor LEE011	N/A	N/A	N/A	inhibitor	CDK4/6 inhibitor	NCT01237236	Advanced cancer A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma	I	1	
CDK4/6	CDK6	1021	LY2835219	CDK4/6 Dual Inhibitor LY2835219	CS1229	71576678	N/A	inhibitor	CDK4/6 inhibitor	NCT01394016	Advanced Cancer A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer	I	1	
CDK4/6	CDK6	1021	Palbociblib	PD0332991	CID 5330286	5330286	N/A	inhibitor	CDK4/6 inhibitor	NCT01037790	Recurrent Ovarian Cancer Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	II	1	
CDK4/6	CDK6	1021	Palbociblib	PD0332991	CID 5330286	5330286	N/A	inhibitor	CDK4/6 inhibitor	NCT01536743	Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression	II	1	
CDK1, 2, 3, 4, 7, 9	CDK7	1022	BAY 1000394	pan-CDK Inhibitor BAY1000394	N/A	N/A	N/A	inhibitor	pan-CDK inhibitor	NCT01188252	Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies	I	1	
CDK1, 2, 3, 4, 7, 9	CDK9	1025	BAY 1000394	pan-CDK Inhibitor BAY1000394	N/A	N/A	N/A	inhibitor	pan-CDK inhibitor	NCT01188252	Advanced Cancer Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies	I	1	
CDK1, 2, 5, 9	CDK9	1025	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
CDK1, 2, 5, 9	CDK9	1025	Dinaciclib	SCH 727965, CDK inhibitor SCH 727965	dinaciclib	46926350	N/A	inhibitor	CDK inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	1	
FLT3	CFLAR	8837	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
FLIP	CFLAR	8837	Idronoxil	Phenoxodiol	Dehydroequol	219100	N/A	inhibitor	Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	1	
FLT3	CFLAR	8837	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
FLT3	CFLAR	8837	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
FLT3	CFLAR	8837	Cabozantanib	Cabozantinib, Cometriq	Cabozantinib	25102847	N/A	inhibitor	RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
TORC1/2	CRTC1	23373	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01343498	Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors	I	1	
TORC1/2	CRTC1	23373	PF-04691502, PF-05212384	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-587	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
TORC1/2	CRTC1	23373	DS-7423	N/A	N/A	N/A	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01364844	Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors	I	1	
TORC1/2	CRTC1	23373	SAR245409	XL765, PI3K/mTOR Dual Kinase Inhibitor XL765	XL765	49867926	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
TORC1/2	CRTC1	23373	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
TORC1/2	CRTC1	23373	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01508104	Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors	I	1	
TORC1/2	CRTC1	23373	DS-3078a	TORC1/2 Kinase Inhibitor DS-3078a	N/A	N/A	N/A	inhibitor	TORC1/2 kinase inhibitor	NCT01588678	Advanced ovarian cancer A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas	I	1	
TORC1/2	CRTC1	23373	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	1	
TORC1/2	CRTC2	200186	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01343498	Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors	I	1	
TORC1/2	CRTC2	200186	PF-04691502, PF-05212384	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-587	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
TORC1/2	CRTC2	200186	DS-7423	N/A	N/A	N/A	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01364844	Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors	I	1	
TORC1/2	CRTC2	200186	SAR245409	XL765, PI3K/mTOR Dual Kinase Inhibitor XL765	XL765	49867926	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
TORC1/2	CRTC2	200186	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
TORC1/2	CRTC2	200186	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01508104	Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors	I	1	
TORC1/2	CRTC2	200186	DS-3078a	TORC1/2 Kinase Inhibitor DS-3078a	N/A	N/A	N/A	inhibitor	TORC1/2 kinase inhibitor	NCT01588678	Advanced ovarian cancer A Phase 1, Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas	I	1	
TORC1/2	CRTC2	200186	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	1	
CSFR1	CSF1R	1436	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
CTLA-4	CTLA-4	1493	Ipilumumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Ipilimumab	N/A	131273201	antagonist	CTLA-4 antagonist	NCT01611558	Platinum-sensitive recurrent ovarian cancer A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects With Residual Measurable Disease	II	1	
Dihydrofolate reductase (DHFR)	DHFR	1719	Pemetrexed	Alimta, Pemetrexed disodium	pemetrexed	446556	N/A	inhibitor	DHFR and Thymidylate synthase inhibitor	NCT01172028	Advanced, recurrent solid tumor Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors	I	1	
Dihydrofolate reductase (DHFR)	DHFR	1719	Pemetrexed	Alimta, Pemetrexed disodium	pemetrexed	446556	N/A	inhibitor	DHFR and Thymidylate synthase inhibitor	NCT01567384	Advanced Cancer A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies	I	1	
Dihydrofolate reductase (DHFR)	DHFR	1719	Pralatrexate	Folotyn, PDX	Pralatrexate	148121	N/A	inhibitor	RFC-1 targeted DHFR inhibitor	NCT01188876	Platinum sensitive relapsed ovarian cancer Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer	I/II	1	
Dihydrofolate reductase (DHFR)	DHFR	1719	Pemetrexed	Alimta, Pemetrexed disodium	pemetrexed	446556	N/A	inhibitor	DHFR and Thymidylate synthase inhibitor	NCT01001910	Platinum sensitive relapsed ovarian cancer Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer	II	1	
EGFR	EGFR	1956	Lapatinib	lapatinib ditosylate, Tykerb	Lapatinib	208908	N/A	inhibitor	HER2 and EGFR kinase inhibitor	NCT00313599	Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors	I	1	
EGFR	EGFR	1956	Panitumumab	ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, Vectibix	AKOS004227608	50070211	N/A	inhibitor	EGFR inhibitor	NCT00610948	Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies	I	1	
EGFR	EGFR	1956	Erlotinib	Tarceva	Erlotinib	176870	N/A	inhibitor	EGFR inhibitor	NCT00770263	Advanced solid tumors Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies	I	1	
EGFR	EGFR	1956	Lapatinib	lapatinib ditosylate, Tykerb	Lapatinib	208908	N/A	inhibitor	HER2 and EGFR kinase inhibitor	NCT01245205	Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer	I	1	
EGFR	EGFR	1956	Vandetanib	AZD6474, Zactima, ZD6474	Vandetanib	3081361	N/A	inhibitor	VEGFR, EGFR, and RET inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
EGFR	EGFR	1956	Panitumumab	ABX-EGF Monoclonal Antibody, ABX-EGF, Clone E7.6.3, Vectibix	AKOS004227608	50070211	N/A	inhibitor	EGFR inhibitor	NCT01296035	Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.	II	1	
EphA2	EPHA2	1969	siRNA-EphA2-DOPC	N/A	N/A	N/A	N/A	inhibitor	EphA2 inhibitor	NCT01591356	Advanced ovarian cancer EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial	I	1	
HER2	ERBB2	2064	Trastuzumab	Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin	Trastuzumab	N/A	50067185	antagonist	HER2 antagonist	NCT01235897	Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab	Ib	1	
HER2	ERBB3	2064	MGAH22	anti-HER2 mAb MGAH22, anti-HER2/c-erbB2 monoclonal antibody	MGAH22	N/A	160698529	antagonist	HER2 antagonist	NCT01148849	HER2 positive recurrent carcinoma A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available	I	1	
ErbB3/HER3	ERBB3	2065	MM-121	SAR256212	CHEMBL2109402	N/A	160698530	inhibitor	ErbB3/Her3 inhibitor	NCT01209195	Locally advanced/metastatic or recurrent epithelial ovarian cancer A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers	I	1	
ErbB3/HER3	ERBB3	2065	MM-121	SAR256212	CHEMBL2109402	N/A	160698530	inhibitor	ErbB3/Her3 inhibitor	NCT01436565	Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers	I	1	
HER2	ERBB4	2064	Pb-TCMC-Trastuzumab	N/A	N/A	N/A	N/A	radioimmunotherapy	HER2-targeted radioimmunotherapy	NCT01384253	HER2+ recurrent ovarian cancer Safety Study of Pb-TCMC-Trastuzumab Radio Immunotherapy	I	1	
HER2	ERBB5	2064	Lapatinib	lapatinib ditosylate, Tykerb	Lapatinib	208908	208908	inhibitor	HER2 and EGFR kinase inhibitor	NCT00313599	Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors	I	1	
HER2	ERBB6	2064	Lapatinib	lapatinib ditosylate, Tykerb	Lapatinib	208908	208908	inhibitor	HER2 and EGFR kinase inhibitor	NCT01245205	Advanced Solid Tumors A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer	I	1	
ER	ESR1	2099	Endoxifen	z-Endoxifen	Endoxifen	10090750	N/A	antagonist	ER antagonist	NCT01273168	Ovarian cancer did not respond to conventional treatment Endoxifen in Adults With Hormone Receptor-Positive Solid Tumors	I	1	
Folate receptor 1	ESR1	2099	IMGN853	Anti-FOLR1-mab Maytansinoid Conjugate, M9346A-sulfo-SPDB-DM4	N/A	N/A	N/A	stabilizer	FOLR1-targeted microtubule stabilizer	NCT01609556	Advanced ovarian cancer A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors	I	1	
Folate receptor 1	ESR1	2099	Vintafolide	EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109	EC145	71301286	N/A	inhibitor	Folate-targeted tubulin inhibitor	NCT01688791	Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers	I	1	
ER	ESR1	2099	Tamoxifen	N/A	tamoxifen	2733526	N/A	antagonist	ER antagonist	NCT01685255	Biochemical recurrent epithelial ovarian cancer A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY	II	1	
Folate receptor 1	ESR1	2099	Vintafolide	EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109	EC145	71301286	N/A	inhibitor	Folate-targeted tubulin inhibitor	NCT01170650	primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED)	III	1	
FGFR	FGFR1	2260	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
FGFR	FGFR1	2260	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
FGFR	FGFR1	2260	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
FGFR	FGFR1	2260	ENMD-2076	N/A	ENMD-2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
FGFR	FGFR2	2263	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
FGFR	FGFR2	2263	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
FGFR	FGFR2	2263	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
FGFR	FGFR2	2263	ENMD-2076	N/A	ENMD-2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
FGFR	FGFR3	2261	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
FGFR	FGFR3	2261	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
FGFR	FGFR3	2261	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
FGFR	FGFR3	2261	ENMD-2076	N/A	ENMD-2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
FGFR	FGFR4	2264	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
FGFR	FGFR4	2264	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
FGFR	FGFR4	2264	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
FGFR	FGFR4	2264	ENMD-2076	N/A	ENMD-2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT00610948	Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01087554	Advanced solid tumors A Phase I Trial of Sirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01122199	Metastatic solid tumor refractory to standard therapies Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01281514	Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01596140	B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01624766	Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies	I	1	
FKBP-12	FKBP1A	2280	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01031381	Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV)	II	1	
VEGFR2	FLK1	3791	Sorafenib	BAY 43-9006, BAY 43-9006 tosylate salt, Nexavar	Sorafenib	216239	N/A	inhibitors	RAF, VEGFR2, and PDGFR-beta inhibitors	NCT01303341	Advanced solid tumors A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma	I	1	
VEGFR1, 2, 3	FLK1	3791	Cediranib	AZD2171, Cediranib maleate, Recentin	Cediranib	9933475	N/A	inhibitor	VEGFR inhibitor	NCT01364051	Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies	I	1	
VEGFR1, 2, 3	FLK1	3791	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
VEGFR	FLK1	3791	Vandetanib	AZD6474, Zactima, ZD6474	Vandetanib	3081361	N/A	inhibitor	VEGFR, EGFR, and RET inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
VEGFR1, 2, 3	FLK1	3791	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
VEGFR1, 2, 3	FLK1	3791	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
VEGFR	FLK1	3791	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
VEGFR	FLK1	3791	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
VEGFR1, 2, 3	FLK1	3791	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
VEGFR	FLK1	3791	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
VEGFR2	FLK1	3791	Cabozantanib	Cabozantinib, Cometriq	Cabozantinib	25102847	N/A	inhibitor	RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
VEGFR1, 2, 3	FLK1	3791	Tivozanib	AV-951	tivozanib	9911830	N/A	inhibitor	VEGFR inhibitor	NCT01853644	Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	II	1	
VEGFR	FLK1	3791	ENMD-2076	N/A	ENMD 2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
VEGFR1, 2, 3	FLT1	2321	Cediranib	AZD2171, Cediranib maleate, Recentin	Cediranib	9933475	N/A	inhibitor	VEGFR inhibitor	NCT01364051	Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies	I	1	
VEGFR1, 2, 3	FLT1	2321	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
VEGFR	FLT1	2321	Vandetanib	AZD6474, Zactima, ZD6474	Vandetanib	3081361	N/A	inhibitor	VEGFR, EGFR, and RET inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
VEGFR1, 2, 3	FLT1	2321	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
VEGFR1, 2, 3	FLT1	2321	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
VEGFR	FLT1	2321	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
VEGFR	FLT1	2321	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
VEGFR1, 2, 3	FLT1	2321	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
VEGFR	FLT1	2321	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
VEGFR1, 2, 3	FLT1	2321	Tivozanib	AV-951	tivozanib	9911830	N/A	inhibitor	VEGFR inhibitor	NCT01853644	Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	II	1	
VEGFR	FLT1	2321	ENMD-2076	N/A	ENMD 2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
VEGFR1, 2, 3	FLT4	2324	Cediranib	AZD2171, Cediranib maleate, Recentin	Cediranib	9933475	N/A	inhibitor	VEGFR inhibitor	NCT01364051	Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies	I	1	
VEGFR1, 2, 3	FLT4	2324	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
VEGFR	FLT4	2324	Vandetanib	AZD6474, Zactima, ZD6474	Vandetanib	3081361	N/A	inhibitor	VEGFR, EGFR, and RET inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
VEGFR1, 2, 3	FLT4	2324	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
VEGFR1, 2, 3	FLT4	2324	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
VEGFR	FLT4	2324	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
VEGFR	FLT4	2324	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
VEGFR1, 2, 3	FLT4	2324	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
VEGFR	FLT4	2324	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
VEGFR1, 2, 3	FLT4	2324	Tivozanib	AV-951	tivozanib	9911830	N/A	inhibitor	VEGFR inhibitor	NCT01853644	Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer	II	1	
VEGFR	FLT4	2324	ENMD-2076	N/A	ENMD 2076	16041424	N/A	inhibitor	Aurora A and VEGFR/FGFR kinase inhibitor	NCT01914510	Ovarian Clear Cell Carcinoma Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas	II	1	
PSMA	FOLH1	2346	PSMA-targeted Docetaxel Nanoparticles BIND-014	BIND-014	Docetaxel	148124	N/A	inhibitor	Tubulin inhibitor	NCT01300533	Advanced ovarian cancer not responsive to standard therapies A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer	I	1	
ALK1 ligands (TGFbeta family)	GDF2	2658	Dalantercept	ACE-041, ALK1-Fc Fusion Protein ACE-041	Dalantercept	N/A	160693095	inhibitor	ALK1 inhibitor	NCT01720173	Recurrent epithelial ovarian cancer A Phase II Evaluation of Dalantercept (NSC #75172, IND #116598), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
HDAC	HDAC10	9735	Vorinostat	SAHA, SuberoylaN/Aide hydroxamic acid, Zolinza	Vorinostat	5311	N/A	inhibitor	HDAC inhibitor	NCT01087554	Advanced solid tumors A Phase I Trial of Sirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer	I	1	
HDAC	HDAC11	9736	Vorinostat	SAHA, SuberoylaN/Aide hydroxamic acid, Zolinza	Vorinostat	5311	N/A	inhibitor	HDAC inhibitor	NCT01266057	Advanced or metastatic cancers A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies	I	1	
HDAC	HDAC9	9734	Vorinostat	SAHA, SuberoylaN/Aide hydroxamic acid, Zolinza	Vorinostat	5311	N/A	inhibitor	HDAC inhibitor	NCT00976183	Stage III/IV ovarian cancer cancer, not have received chemotherapy yet Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma	I/II	1	
HIF1-alpha	HIF1A	3091	CRLX101	camptothecin-polymer conjugate IT-101, cyclodextrin-based polymer-camptothecin CRLX101, IT-101	N/A	N/A	N/A	HIF-1alpha	dual inhibitor of topoisomerase 1 and HIF-1alpha	NCT01652079	Recurrent epithelial cancer A Phase II, 2-stage Trial of CRLX101-202 in Recurrent Ovarian, Tubal and Peritoneal Cancer	II	1	
HMG-CoA reductase	HMGCR	3156	Lovastatin	Mevacor, Mevinolin, Monacolin-K	lovastatin	53232	N/A	inhibitor	HMG-CoA reductase inhibitor	NCT00585052	Platinum-refractory or -resistant ovarian cancer A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer	II	1	
3-dioxygenase	IDO1	3620	INCB024360	3-dioxygenase Inhibitor INCB024360, IDO1 Inhibitor INCB024360, Indoleamine-2	N/A	N/A	N/A	inhibitor	3-dioxygenase (INDO) inhibitor	NCT01685255	Biochemical recurrent epithelial ovarian cancer A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY	II	1	
IGF1R	IGF1R	3480	AMG 479	N/A	N/A	N/A	N/A	inhibitor	IGF1R inhibitor	NCT01122199	Metastatic solid tumor refractory to standard therapies Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors	I	1	
IGF1R	IGF1R	3480	Linsitinib	OSI-906	Linsitinib	11640390	N/A	inhibitor	IGF1R inhibitor	NCT01567384	Advanced Cancer A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies	I	1	
IGF1R	IGF1R	3480	AMG 479	N/A	N/A	N/A	N/A	inhibitor	IGF1R inhibitor	NCT01708161	Advanced ovarian cancer with PIK3CA mutation A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors	I/II	1	
IL-12	IL-12A	3592	EGEN-001	phIL-12-005/PPC	CID 446414	446414	N/A	unknown	N/A	NCT01489371	Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	I	1	
IL-12	IL-12B	3593	EGEN-001	phIL-12-005/PPC	CID 446414	446414	N/A	unknown	N/A	NCT01489371	Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	I	1	
IL-1R	IL-1R1	3554	Anakinra	N/A	Anakinra	N/A	53790816	antagonist	IL-1 receptor antagonist	NCT01624766	Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies	I	1	
IL-1R	IL-1R2	7850	Anakinra	N/A	Anakinra	N/A	53790816	antagonist	IL-1 receptor antagonist	NCT01624766	Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies	I	1	
indoleamine 2	INDO2	169355	INCB024360	3-dioxygenase Inhibitor INCB024360, IDO1 Inhibitor INCB024360, Indoleamine-2	N/A	N/A	N/A	inihibitor	3-dioxygenase (INDO) inhibitor, indoleamine 2	NCT01685255	Biochemical recurrent epithelial ovarian cancer A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF THE IDO INHIBITOR INCB024360 VERSUS TAMOXIFEN FOR SUBJECTS WITH BIOCHEMICAL-RECURRENT-ONLY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CARCINOMA, OR FALLOPIAN TUBE CANCER FOLLOWING COMPLETE REMISSION WITH FIRST-LINE CHEMOTHERAPY	II	1	
RTK	KDR	3791	Cabozantanib	Cabozantinib, Cometriq	Cabozantinib	25102847	N/A	inhibitor	RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
KIR (killer-cell Ig-like receptors)	KIR3DL3	115653	BMS-986015	Anti-KIR mab IPH2102, IPH2102	N/A	N/A	N/A	activator	NK cell activator	NCT01714739	Advanced ovarian cancer A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination With Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors	I	1	
cKIT	KIT	3815	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
p38 MAPK (MAPK14)	MAPK14	1432	LY2228820	N/A	LY2228820	11570805	N/A	inhibitor	p38 mitogen-activated protein kinase (MAPKs) inhib	NCT01663857	Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer	I/II	1	
MEK	MEK1	5604	GDC-0973	XL518	XL518	16222096	N/A	inhibitor	MEK inhibitor	NCT00996892	Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	i	1	
MEK	MEK1	5604	Trametinib	GSK1120212, JTP-74057, MEK Inhibitor GSK1120212	Trametinib	11707110	N/A	inhibitor	MEK 1/2 inhibitor	NCT01138085	Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2)	I	1	
MEK	MEK1	5604	Trametinib	GSK1120212, JTP-74057, MEK Inhibitor GSK1120212	Trametinib	11707110	N/A	inhibitor	MEK 1/2 inhibitor	NCT01248858	Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.	I	1	
MEK	MEK1	5604	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01363232	NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors	I	1	
MEK	MEK1	5604	Selumetinib	ARRY-142886, AZD6244	Selumetinib	10127622	N/A	inhibitor	MEK inhibitor	NCT01364051	Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies	I	1	
MEK	MEK1	5604	Pimasertib	AS703026, EMD 1036239, MSC1936369B	Pimasertib	44187362	N/A	inhibitor	MEK1/2 inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
MEK	MEK1	5604	Trametinib	GSK1120212, JTP-74057, MEK Inhibitor GSK1120212	Trametinib	11707110	N/A	inhibitor	MEK 1/2 inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
MEK	MEK1	5604	MSC2015103B	N/A	N/A	N/A	N/A	inhibitor	MEK inhibitor	NCT01453387	Advanced Cancer MSC2015103B in Solid Tumors	I	1	
MEK	MEK1	5604	WX-554	N/A	N/A	N/A	N/A	inhibitor	MEK inhibitor	NCT01581060	Advanced solid tumors A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours	I	1	
MEK	MEK1	5604	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01649336	Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	I	1	
MEK	MEK1	5604	Rafametinib	BAY86-9766, RDEA119	BAY 869766	44182295	N/A	inhibitor	MEK inhibitor	NCT01392521	Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ib	1	
MEK	MEK1	5604	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01449058	Advanced BRAF or KRAS mutant cancers A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ib	1	
MEK	MEK1	5604	GDC-0973	XL518	XL518	16222096	N/A	inhibitor	MEK inhibitor	NCT01562275	Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors	Ib	1	
MEK	MEK1	5604	TAK-733	MEK Inhibitor TAK-733	TAK-733	24963252	N/A	inhibitor	MEK inhibitor	NCT01613261	Advanced Solid Tumors A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies	Ib	1	
MEK	MEK1	5604	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK164	10288191	N/A	inhibitor	MEK inhibitor	NCT01543698	Solid Tumors Harboring a BRAF V600 Mutation A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	Ib/II	1	
MEK	MEK1	5604	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	1	
MEK	MEK2	5605	GDC-0973	XL518	XL518	16222096	N/A	inhibitor	MEK inhibitor	NCT00996892	Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	i	1	
MEK	MEK2	5605	Trametinib	GSK1120212, JTP-74057, MEK Inhibitor GSK1120212	Trametinib	11707110	N/A	inhibitor	MEK 1/2 inhibitor	NCT01138085	Advanced Solid Tumors A Phase I Dose Escalation Open-Label Safety and Pharmacokinetic Study to Determine the Recommended Phase II Dose of GSK1120212 Dosed in Combination With GSK2141795 in Subjects With Solid Tumors (Part 1) and in Subjects With Pancreatic Cancer, Endometrial Cancer or Colorectal Cancer (Part 2)	I	1	
MEK	MEK2	5605	Trametinib	GSK1120212, JTP-74057, MEK Inhibitor GSK1120212	Trametinib	11707110	N/A	inhibitor	MEK 1/2 inhibitor	NCT01248858	Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.	I	1	
MEK	MEK2	5605	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01363232	NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors	I	1	
MEK	MEK2	5605	Selumetinib	ARRY-142886, AZD6244	Selumetinib	10127622	N/A	inhibitor	MEK inhibitor	NCT01364051	Melanoma (Skin); Unspecified Adult Solid Tumor, Protocol Specific Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies	I	1	
MEK	MEK2	5605	Pimasertib	AS703026, EMD 1036239, MSC1936369B	Pimasertib	44187362	N/A	inhibitor	MEK1/2 inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
MEK	MEK2	5605	Trametinib	GSK1120212, JTP-74057, MEK Inhibitor GSK1120212	Trametinib	11707110	N/A	inhibitor	MEK 1/2 inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
MEK	MEK2	5605	MSC2015103B	N/A	N/A	N/A	N/A	inhibitor	MEK inhibitor	NCT01453387	Advanced Cancer MSC2015103B in Solid Tumors	I	1	
MEK	MEK2	5605	WX-554	N/A	N/A	N/A	N/A	inhibitor	MEK inhibitor	NCT01581060	Advanced solid tumors A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours	I	1	
MEK	MEK2	5605	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01649336	Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	I	1	
MEK	MEK2	5605	Rafametinib	BAY86-9766, RDEA119	BAY 869766	44182295	N/A	inhibitor	MEK inhibitor	NCT01392521	Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ib	1	
MEK	MEK2	5605	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK162	10288191	N/A	inhibitor	MEK inhibitor	NCT01449058	Advanced BRAF or KRAS mutant cancers A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ib	1	
MEK	MEK2	5605	GDC-0973	XL518	XL518	16222096	N/A	inhibitor	MEK inhibitor	NCT01562275	Locally advanced or metastatic solid tumors A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors	Ib	1	
MEK	MEK2	5605	TAK-733	MEK Inhibitor TAK-733	TAK-733	24963252	N/A	inhibitor	MEK inhibitor	NCT01613261	Advanced Solid Tumors A Multicenter, Open-label, Phase 1b Study of TAK-733 (an Oral MEK Inhibitor) in Combination With Alisertib (an Oral Aurora A Kinase Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies	Ib	1	
MEK	MEK2	5605	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK165	10288191	N/A	inhibitor	MEK inhibitor	NCT01543698	Solid Tumors Harboring a BRAF V600 Mutation A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	Ib/II	1	
MEK	MEK2	5605	MEK162	ARRY-162, ARRY-438162, MEK inhibitor MEK162	MEK163	10288191	N/A	inhibitor	MEK inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	1	
RTK	MET	4233	Cabozantanib	Cabozantinib, Cometriq	Cabozantinib	25102847	N/A	inhibitor	RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT00610948	Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies	I	1	
mTOR	MTOR	2475	Temsirolimus	CCI-779, Torisel	Temsirolimus	6918289	N/A	inhibitor	mTOR inhibitor	NCT00770263	Advanced solid tumors Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies	I	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01087554	Advanced solid tumors A Phase I Trial of Sirolimus (mTOR Inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients With Advanced Cancer	I	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01122199	Metastatic solid tumor refractory to standard therapies Phase I Study of mTOR Inhibitor RAD001 in Combination With IGF-1R Inhibitor AMG479 for Patients With Advanced Solid Tumors	I	1	
mTOR	MTOR	2475	Ridaforolimus	Deforolimus	Deforolimus	11520894	N/A	inhibitor	mTOR inhibitor	NCT01256268	Metastatic or Recurrent Ovarian Cancer elegible for carbo-taxol treatment Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids	I	1	
mTOR	MTOR	2475	Rapamycin	Rapamune, Sirolimus	Sirolimus	5284616	N/A	inhibitor	mTOR inhibitor	NCT01266057	Advanced or metastatic cancers A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies	I	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01281514	Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE	I	1	
mTOR	MTOR	2475	Ridaforolimus	Deforolimus	Deforolimus	11520894	N/A	inhibitor	mTOR inhibitor	NCT01295632	Relapsed or refractory ovarian cancer Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer	I	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
mTOR	MTOR	2475	Temsirolimus	CCI-779, Torisel	Temsirolimus	6918289	N/A	inhibitor	mTOR inhibitor	NCT01529593	Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers	I	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
mTOR	MTOR	2475	Everolimus, Temsirolimus	Afinitor, CCI-779, Certican, RAD001, Torisel, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01596140	B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer	I	1	
mTOR	MTOR	2475	Everolimus, Temsirolimus	Afinitor, CCI-779, Certican, RAD001, Torisel, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01596140	B-RAF mutated advanced solid tumors A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer	I	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01624766	Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies	I	1	
mTOR	MTOR	2475	Temsirolimus	CCI-779, Torisel	Temsirolimus	6918289	N/A	inhibitor	mTOR inhibitor	NCT00982631	Advanced or Recurrent Ovarian Cancer A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer	Ib	1	
mTOR	MTOR	2475	Temsirolimus	CCI-779, Torisel	Temsirolimus	6918289	N/A	inhibitor	mTOR inhibitor	NCT01010126	Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor	II	1	
mTOR	MTOR	2475	Everolimus	Afinitor, Certican, RAD001, Zortress	Everolimus	6442177	N/A	inhibitor	mTOR inhibitor	NCT01031381	Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV)	II	1	
mTOR	MTOR	2475	Temsirolimus	CCI-779, Torisel	Temsirolimus	6918289	N/A	inhibitor	mTOR inhibitor	NCT01196429	Newly diagnosed stage III or stage IV clear cell ovarian cancer. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer	II	1	
CA125	MUC16	94025	DMUC5754A	N/A	N/A	N/A	N/A	unknown	N/A	NCT01335958	Platinum-resistant ovarian cancer A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer	I	1	
CA125	MUC16	94025	Oregovomab	B43.13, Monoclonal Antibody B43.13, OvaRex	N/A	N/A	N/A	antigen	immunological response against cancer antigen	NCT01616303	Newly diagnosed advanced ovarian cancer Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma	II	1	
FGF	N/A	N/A	Lenalidomide	CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	0	Not sure what to do here, there are a large number of VGFs... Maybe drop these...
Tubulin	N/A	N/A	Paclitaxel Albumin-Stabilized Nanoparticle Formulation	ABI-007, Abraxane, nab-paclitaxel	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00313599	Advanced solid cancers A Phase I Dose Escalation Study of a 2 Day Oral Lapatinib Chemosensitization Pulse Given Prior To Weekly Intravenous Abraxane in Patients With Advanced Solid Tumors	I	0	
Tubulin	N/A	N/A	Docetaxel	Taxotere	docetaxel	148124	N/A	inhibitor	Tubulin and VEGF inhibitor	NCT00692900	Platinum-resistant or -sensitive ovarian epithelial cancer Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer	I	0	
Tubulin	N/A	N/A	Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation	ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00825201	Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity	I	0	
Tubulin	N/A	N/A	Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation	ABI-007, Abraxane, Anzatax, Asotax, Bristaxol, nab-paclitaxel, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00825201	Advanced cancer of the peritoneal cavity. Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	0	
20S Proteasome	N/A	N/A	Bortezomib	PS-341, Velcade	Bortezomib	387447	N/A	inhibitor	Proteosome and NF-kappaB inhibitor	NCT01074411	Persistent or recurrent ovarian epithelial cancer Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	0	20S proteasome is not really a gene ... exclude this entry
Tubulin	N/A	N/A	Docetaxel	Taxotere	docetaxel	148124	N/A	inhibitor	Tubulin and VEGF inhibitor	NCT01094288	Advanced Solid Tumors A Phase 1 Study of MLN8237, an Aurora A Kinase Inhibitor, in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen	I	0	
Tubulin	N/A	N/A	Vinorelbine ditartrate	Biovelbin, Eunades, Navelbine, Navelbine ditartrate, NVB, Vinorelbine tartrate, VNB	Navelbin	60779	N/A	inhibitor	Tubulin inhibitor	NCT01104259	BRCA1/2 hereditary ovarian cancer Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer	I	0	
Tubulin	N/A	N/A	Docetaxel	Taxotere	docetaxel	148124	N/A	inhibitor	Tubulin and VEGF inhibitor	NCT01110486	Advanced solid tumors A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as Monotherapy, in Combination With Carboplatin or in Combination With Docetaxel in Subjects With Advanced Solid Tumors	I	0	
Tubulin	N/A	N/A	Docetaxel	Taxotere	docetaxel	148124	N/A	inhibitor	Tubulin and VEGF inhibitor	NCT01172028	Advanced, recurrent solid tumor Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01209195	Locally advanced/metastatic or recurrent epithelial ovarian cancer A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01256268	Metastatic or Recurrent Ovarian Cancer elegible for carbo-taxol treatment Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids	I	0	
lysosome	N/A	N/A	Hydroxychloroquine	PlaqueN/A	hydroxychloroquine	3652	N/A	inhibitor	Autophagy inhibitor	NCT01266057	Advanced or metastatic cancers A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies	I	0	
Tubulin	N/A	N/A	PSMA-targeted Docetaxel Nanoparticles BIND-014	BIND-014	N/A	N/A	N/A	inhibitor	Tubulin inhibitor	NCT01300533	Advanced ovarian cancer not responsive to standard therapies A Phase I, Open Label , Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 Given by IV Infusion to Patients With Advanced or Metastatic Cancer	I	0	
FGF	N/A	N/A	Lenalidomide	CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	0	Not sure what to do here, there are a large number of VGFs... Maybe drop these... (drug is broad acting in anti-angiogenesis)
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01366144	Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01411410	Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy	I	0	
lysosome	N/A	N/A	Hydroxychloroquine	PlaqueN/A	hydroxychloroquine	3652	N/A	inhibitor	Autophagy inhibitor	NCT01480154	Advanced Solid Tumors A Phase I Trial of MK-2206 and Hydroxychloroquine in Solid Tumors, Melanoma, Renal and Prostate Cancer to Examine the Role of Autophagy in Tumorigenesis	I	0	Drug
Tubulin	N/A	N/A	IMGN853	Anti-FOLR1-mab Maytansinoid Conjugate, M9346A-sulfo-SPDB-DM4	N/A	N/A	N/A	stabilizer	FOLR1-targeted microtubule stabilizer	NCT01609556	Advanced ovarian cancer A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01649336	Platinum resistant epithelial ovarian cancer A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01676753	Advanced solid tumors Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression	I	0	
Tubulin	N/A	N/A	Paclitaxel, Vintafolide	Anzatax, Asotax, Bristaxol, EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Folate-targeted tubulin inhibitor, Tubulin and Bcl2 inhibitor	NCT01688791	Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers	I	0	
Tubulin	N/A	N/A	Paclitaxel, Vintafolide	Anzatax, Asotax, Bristaxol, EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Folate-targeted tubulin inhibitor, Tubulin and Bcl2 inhibitor	NCT01688791	Advanced Cancer A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Combinations in Adult Subjects With Advanced Cancers	I	0	
Tubulin	N/A	N/A	ATI1123	Taxotere	N/A	N/A	N/A	inhibitor	Tubulin inhibitor	NCT01715168	Recurrent ovarian cancer A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy	I	0	
DNA-PK	N/A	N/A	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01778803	Adv or refractory ovarian cancer A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer	I	0	
Tubulin	N/A	N/A	ATI1123	Taxotere	N/A	N/A	N/A	inhibitor	Tubulin inhibitor	NCT01815294	Advanced solid tumors A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.	I	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01831089	Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors	I	0	
Tubulin	N/A	N/A	Docetaxel	Taxotere	docetaxel	148124	N/A	inhibitor	Tubulin and VEGF inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00976183	Stage III/IV ovarian cancer cancer, not have received chemotherapy yet Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma	I/II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01091428	Recurrent epithelial ovarian carcinoma MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer	I/II	0	
Tubulin	N/A	N/A	BNC105P	N/A	BNC105p	16678086	N/A	inhibitor	microtubule polymerization inhibitor	NCT01624493	Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse	I/II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01650376	Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients	I/II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01653912	Recurrent platinum-resistant ovarian cancer An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer	I/II	0	
DNA methyltransferase	N/A	N/A	SGI-110	DNA methyltransferase inhibitor SGI-110	UNII-0RB89YH367	71587873	N/A	inhibitor	DNA methyltransferase inhibitor	NCT01696032	Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer	I/II	0	Drug is a hypomethylating agent, no targetting of specific gene
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01696032	Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer	I/II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01711970	Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mllerian Cancer	I/II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01235897	Advanced HER2-overexpressing solid tumors A Phase Ib Dose-escalation Trial of the AKT Inhibitor MK2206 in Combination With Weekly Paclitaxel With or Without Trastuzumab	Ib	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00585052	Platinum-refractory or -resistant ovarian cancer A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer	II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01097746	Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer	II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01196429	Newly diagnosed stage III or stage IV clear cell ovarian cancer. Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer	II	0	
Tubulin	N/A	N/A	Fosbretabulin	Combretastatin A-4 Phosphate, fosbretabulin tromethamine, Zybrestat	Fosbretabulin	5351387	N/A	inhibitor	tubulin polymerization inhibitor	NCT01305213	Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01357161	Platinum-sensitive p53 mutant ovarian cancer A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer	II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01616303	Newly diagnosed advanced ovarian cancer Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma	II	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	0	
Tubulin	N/A	N/A	Paclitaxel, Paclitaxel Poliglumex	Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00108745	Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer	III	0	
Tubulin	N/A	N/A	Paclitaxel, Paclitaxel Poliglumex	Anzatax, Asotax, Bristaxol, paclitaxel-polyglutamate polymer, polyglutamate paclitaxel, polyglutamic acid paclitaxel, Poly-L-Glutamic acid-Paclitaxel Conjugate, Praxel, Taxol, Taxol Konzentrat, TXL, Xyotax	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00108745	Stage III-IV ovarian epithelial cancer Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer	III	0	
Tubulin	N/A	N/A	Docetaxel, Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Taxotere, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor, Tubulin and VEGF inhibitor	NCT00565851	Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	III	0	
Tubulin	N/A	N/A	Docetaxel, Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Taxotere, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor, Tubulin and VEGF inhibitor	NCT00565851	Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	III	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT00954174	Persistent or recurrent ovarian cancer Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer	III	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01167712	Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	III	0	
Tubulin	N/A	N/A	Vintafolide	EC145, Folate-Vinca Alkaloid Conjugate EC145, MK-8109	Paclitaxel	N/A	162109041	inhibitor	Folate-targeted tubulin inhibitor	NCT01170650	primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED)	III	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01239732	Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma	III	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01493505	Newly diagnosed stage III-IV ovarian epithelial cancer A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers	III	0	
Tubulin	N/A	N/A	Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Paclitaxel	36314	N/A	inhibitor	Tubulin and Bcl2 inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	0	
Beta-adrenergic receptors	N/A	N/A	propanolol	Inderal, InnoPranXL	Propranolol	4946	N/A	blocker	Beta blocker	NCT01308944	diagnosed ovarian, fallopian tube, or primary peritoneal cancer Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients	N/A	0	
Beta-adrenergic receptors	N/A	N/A	propanolol	Inderal, InnoPranXL	Propranolol	4946	N/A	blocker	Beta blocker	NCT01504126	diagnosed epithelial ovarian cancer Feasibility Study: Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients	N/A	0	Drug is beta-blocker. Clinical trial is testing it's ability to amplify taxol
NF-kappaB	NFKB1	4790	Bortezomib	PS-341, Velcade	Bortezomib	387447	N/A	inhibitor	Proteosome and NF-kappaB inhibitor	NCT01074411	Persistent or recurrent ovarian epithelial cancer Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	
Trk	NTRK1	4914	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
p53	P53	7157	Kevetrin	Thioureidobutyronitrile	granisetron	5284566	N/A	activator	p53 activator	NCT01664000	Advanced solid tumors A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT00892736	Malignant solid tumors that did not respond to previous therapy ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01104259	BRCA1/2 hereditary ovarian cancer Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01145430	Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01233505	Metastatic mucinous ovarian cancer and/or BRCA1/2 mutant Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	I	1	
PARP1/2	PARP1	142	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01237067	Ovarian cancer did not respond to conventional treatment Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers	I	1	
PARP1/2	PARP1	142	BMN-673	N/A	1207456-01-6	44819241	N/A	inhibitor	PARP inhibitor	NCT01286987	Advanced ovarian cancer A Phase 1, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Patients With Advanced or Recurrent Solid Tumors	I	1	
PARP1/2	PARP1	142	ABT-767	N/A	N/A	N/A	N/A	inhibitor	PARP inhibitor	NCT01339650	Advanced BRCA1 or BRCA2-mutated solid tumors and high grade serous ovarian, fallopian tube, or primary peritoneal cancer A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01366144	Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01434316	BRCA1/2 carriers, advanced solid tumors Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors	I	1	
PARP1/2	PARP1	142	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01445418	Metastatic epithelial ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer who have failed prior therapy A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01459380	Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer	I	1	
PARP1/2	PARP1	142	E7449	N/A	N/A	N/A	N/A	inhibitor	PARP inhibitor	NCT01618136	Advanced solid tumors An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors	I	1	
PARP1/2	PARP1	142	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01623349	Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01749397	Recurrent (metastatic) epithelial ovarian cancer A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01853306	Platinum-sensitive recurrent BRCA1/2 mutated or G3 serous ovarian cancer A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors	I	1	
PARP1/2	PARP1	142	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01012817	Platinum-refractory or recurrent (< 1yr after Pt treatment) ovarian epithelial or primary peritoneal cancer A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy	I/II	1	
PARP1/2	PARP1	142	Rucaparib	AG014699, PF-01367338	RUCAPARIB	9931954	N/A	inhibitor	PARP inhibitor	NCT01482715	gBRCA mutation ovarian cancer, platinum sensitive A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor	I/II	1	
PARP1/2	PARP1	142	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01650376	Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients	I/II	1	
PARP1/2	PARP1	142	Niraparib	MK4827	Niraparib	24958200	N/A	inhibitor	PARP inhibitor	NCT01847274	Platinum-sensitive G3 serous (or germline BRCA) ovarian cancer A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	III	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT00892736	Malignant solid tumors that did not respond to previous therapy ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01104259	BRCA1/2 hereditary ovarian cancer Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01145430	Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01233505	Metastatic mucinous ovarian cancer and/or BRCA1/2 mutant Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	I	1	
PARP1/2	PARP2	10038	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01237067	Ovarian cancer did not respond to conventional treatment Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers	I	1	
PARP1/2	PARP2	10038	BMN-673	N/A	1207456-01-6	44819241	N/A	inhibitor	PARP inhibitor	NCT01286987	Advanced ovarian cancer A Phase 1, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered BMN 673 in Patients With Advanced or Recurrent Solid Tumors	I	1	
PARP1/2	PARP2	10038	ABT-767	N/A	N/A	N/A	N/A	inhibitor	PARP inhibitor	NCT01339650	Advanced BRCA1 or BRCA2-mutated solid tumors and high grade serous ovarian, fallopian tube, or primary peritoneal cancer A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01366144	Recurrent or stage IV ovarian cancer An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01434316	BRCA1/2 carriers, advanced solid tumors Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors	I	1	
PARP1/2	PARP2	10038	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01445418	Metastatic epithelial ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer who have failed prior therapy A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01459380	Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer	I	1	
PARP1/2	PARP2	10038	E7449	N/A	N/A	N/A	N/A	inhibitor	PARP inhibitor	NCT01618136	Advanced solid tumors An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors	I	1	
PARP1/2	PARP2	10038	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01623349	Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01749397	Recurrent (metastatic) epithelial ovarian cancer A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01853306	Platinum-sensitive recurrent BRCA1/2 mutated or G3 serous ovarian cancer A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib in Subjects With Solid Tumors	I	1	
PARP1/2	PARP2	10038	Veliparib	ABT-888	Veliparib	11960529	N/A	inhibitor	PARP inhibitor	NCT01012817	Platinum-refractory or recurrent (< 1yr after Pt treatment) ovarian epithelial or primary peritoneal cancer A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy	I/II	1	
PARP1/2	PARP2	10038	Rucaparib	AG014699, PF-01367338	RUCAPARIB	9931954	N/A	inhibitor	PARP inhibitor	NCT01482715	gBRCA mutation ovarian cancer, platinum sensitive A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor	I/II	1	
PARP1/2	PARP2	10038	Olaparib	AZD2281	Olaparib	23725625	N/A	inhibitor	PARP inhibitor	NCT01650376	Relapsed ovarian cancer Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients	I/II	1	
PARP1/2	PARP2	10038	Niraparib	MK4827	Niraparib	24958200	N/A	inhibitor	PARP inhibitor	NCT01847274	Platinum-sensitive G3 serous (or germline BRCA) ovarian cancer A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer	III	1	
PD-1 receptor	PDCD1	5133	BMS-936558	Anti-PD-1 human mab MDX-1106, MDX-1106, nivolumab, ONO-4538	Nivolumab	N/A	160698453	blocker	blocks PDL-1/2-dependent negative regulation of T	NCT01714739	Advanced ovarian cancer A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination With Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors	I	1	
PDGFR	PDGFRA	5156	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
PDGFR	PDGFRA	5156	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
PDGFR	PDGFRA	5156	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
PDGFR	PDGFRA	5156	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
PDGFR	PDGFRA	5156	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
PDGFR	PDGFRA	5156	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
PDGFR	PDGFRA	5156	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
PDGFRb	PDGFRB	5159	Sorafenib	BAY 43-9006, BAY 43-9006 tosylate salt, Nexavar	Sorafenib	216239	N/A	inhibitor	RAF, VEGFR2, and PDGFR-beta inhibitors	NCT01303341	Advanced solid tumors A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma	I	1	
PDGFR	PDGFRB	5159	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01438554	Advanced Cancer Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer	I	1	
PDGFR	PDGFRB	5159	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced Solid Tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
PDGFR	PDGFRB	5159	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01639911	Advanced solid tumors Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors	I	1	
PDGFR	PDGFRB	5159	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
PDGFR	PDGFRB	5159	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
PDGFR	PDGFRB	5159	Pazopanib	Votrient	Pazopani	10113978	N/A	inhibitor	VEFGR, c-Kit, and PDGFR inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
PDGFR	PDGFRB	5159	Nintedanib	BIBF 1120, Vargatef	Nintedanib	56843413	N/A	inhibitor	VEGFR, FGFR, PDGFR, and FLT3 inhibitor	NCT01669798	Bevacizumab resistant recurrent ovarian cancer Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma	II	1	
PI3K	PI3KCA	5290	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT00962611	Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer	I	1	
PI3K	PI3KCA	5290	GDC-0941	N/A	GDC-0941	17755052	N/A	inhibitor	pan-PI3K inhibitor	NCT00996892	Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	i	1	
PI3K alpha	PI3KCA	5290	BYL719	P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719	BYL719	56649450	N/A	inhibitor	PI3K inhibitor	NCT01219699	Advanced cancerwith PIK3CA gene alteration A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene	I	1	
PI3K	PI3KCA	5290	GSK2126458	PI3K Inhibitor GSK2126458	GSK2126458	25167777	N/A	inhibitor	pan-PI3K inhibitor	NCT01248858	Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.	I	1	
PI3K	PI3KCA	5290	ZSTK474	N/A	ZSTK474	11647372	N/A	inhibitor	pan-PI3K inhibitor	NCT01280487	Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer	I	1	
PI3K	PI3KCA	5290	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01343498	Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors	I	1	
PI3K	PI3KCA	5290	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-587	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCA	5290	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-591	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCA	5290	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01363232	NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors	I	1	
PI3K	PI3KCA	5290	DS-7423	N/A	N/A	N/A	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01364844	Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors	I	1	
PI3K alpha	PI3KCA	5290	BYL719	P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719	BYL719	56649450	N/A	inhibitor	PI3K inhibitor	NCT01387321	Advanced Cancer A Study of BYL719 in Adult Patients With Advanced Solid Malignancies	I	1	
PI3K	PI3KCA	5290	SAR245409	XL765, PI3K/mTOR Dual Kinase Inhibitor XL765	XL765	49867926	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
PI3K	PI3KCA	5290	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01411410	Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy	I	1	
PI3K	PI3KCA	5290	SAR245408	XL147	XL147	1893730	N/A	inhibitor	pan-PI3K inhibitor	NCT01436565	Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers	I	1	
PI3K alpha	PI3KCA	5290	MLN-1117	INK-1117	N/A	N/A	N/A	inhibitor	PI3K inhibitor	NCT01449370	Advanced solid tumors A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease	I	1	
PI3K	PI3KCA	5290	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
PI3K	PI3KCA	5290	BEZ235	NYP-BEZ235	NVP-BEZ235	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
PI3K	PI3KCA	5290	BEZ235	NYP-BEZ235	NVP-BEZ239	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01508104	Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors	I	1	
PI3K	PI3KCA	5290	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01623349	Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer	I	1	
PI3K	PI3KCA	5290	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	1	
PI3K alpha	PI3KCA	5290	BYL719	P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719	BYL719	56649450	N/A	inhibitor	PI3K inhibitor	NCT01708161	Advanced ovarian cancer with PIK3CA mutation A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors	I/II	1	
PI3K	PI3KCA	5290	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01392521	Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ib	1	
PI3K alpha	PI3KCA	5290	BYL719	P13K Inhibitor BYL719, phosphoinositide 3-Kinase inhibitor BYL719	BYL719	56649450	N/A	inhibitor	PI3K inhibitor	NCT01449058	Advanced BRAF or KRAS mutant cancers A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Ib	1	
PI3K	PI3KCA	5290	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01550380	Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers	II	1	
PI3K	PI3KCB	5291	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT00962611	Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer	I	1	
PI3K	PI3KCB	5291	GDC-0941	N/A	GDC-0942	17755052	N/A	inhibitor	pan-PI3K inhibitor	NCT00996892	Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	i	1	
PI3K	PI3KCB	5291	GSK2126458	PI3K Inhibitor GSK2126458	GSK2126458	25167777	N/A	inhibitor	pan-PI3K inhibitor	NCT01248858	Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.	I	1	
PI3K	PI3KCB	5291	ZSTK474	N/A	ZSTK474	11647372	N/A	inhibitor	pan-PI3K inhibitor	NCT01280487	Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer	I	1	
PI3K	PI3KCB	5291	BEZ235	NYP-BEZ235	NVP-BEZ236	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01343498	Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors	I	1	
PI3K	PI3KCB	5291	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-588	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCB	5291	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-592	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCB	5291	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01363232	NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors	I	1	
PI3K	PI3KCB	5291	DS-7423	N/A	N/A	N/A	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01364844	Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors	I	1	
PI3K	PI3KCB	5291	SAR245409	XL765, PI3K/mTOR Dual Kinase Inhibitor XL765	XL765	49867926	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
PI3K	PI3KCB	5291	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01411410	Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy	I	1	
PI3K	PI3KCB	5291	SAR245408	XL147	XL147	1893730	N/A	inhibitor	pan-PI3K inhibitor	NCT01436565	Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers	I	1	
PI3K	PI3KCB	5291	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
PI3K	PI3KCB	5291	BEZ235	NYP-BEZ235	NVP-BEZ236	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
PI3K	PI3KCB	5291	BEZ235	NYP-BEZ235	NVP-BEZ240	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01508104	Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors	I	1	
PI3K	PI3KCB	5291	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01623349	Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer	I	1	
PI3K	PI3KCB	5291	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	1	
PI3K	PI3KCB	5291	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01392521	Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ib	1	
PI3K	PI3KCB	5291	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01550380	Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers	II	1	
PI3K	PI3KCD	5293	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT00962611	Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer	I	1	
PI3K	PI3KCD	5293	GDC-0941	N/A	GDC-0944	17755052	N/A	inhibitor	pan-PI3K inhibitor	NCT00996892	Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	i	1	
PI3K	PI3KCD	5293	GSK2126458	PI3K Inhibitor GSK2126458	GSK2126458	25167777	N/A	inhibitor	pan-PI3K inhibitor	NCT01248858	Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.	I	1	
PI3K	PI3KCD	5293	ZSTK474	N/A	ZSTK474	11647372	N/A	inhibitor	pan-PI3K inhibitor	NCT01280487	Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer	I	1	
PI3K	PI3KCD	5293	BEZ235	NYP-BEZ235	NVP-BEZ238	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01343498	Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors	I	1	
PI3K	PI3KCD	5293	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-590	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCD	5293	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-594	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCD	5293	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01363232	NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors	I	1	
PI3K	PI3KCD	5293	DS-7423	N/A	N/A	N/A	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01364844	Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors	I	1	
PI3K	PI3KCD	5293	SAR245409	XL765, PI3K/mTOR Dual Kinase Inhibitor XL765	XL765	49867926	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
PI3K	PI3KCD	5293	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01411410	Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy	I	1	
PI3K	PI3KCD	5293	SAR245408	XL147	XL147	1893730	N/A	inhibitor	pan-PI3K inhibitor	NCT01436565	Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers	I	1	
PI3K	PI3KCD	5293	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
PI3K	PI3KCD	5293	BEZ235	NYP-BEZ235	NVP-BEZ238	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
PI3K	PI3KCD	5293	BEZ235	NYP-BEZ235	NVP-BEZ242	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01508104	Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors	I	1	
PI3K	PI3KCD	5293	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01623349	Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer	I	1	
PI3K	PI3KCD	5293	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	1	
PI3K	PI3KCD	5293	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01392521	Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ib	1	
PI3K	PI3KCD	5293	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01550380	Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers	II	1	
PI3K	PI3KCG	5294	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT00962611	Advanced Cancer BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer	I	1	
PI3K	PI3KCG	5294	GDC-0941	N/A	GDC-0943	17755052	N/A	inhibitor	pan-PI3K inhibitor	NCT00996892	Advanced Cancer A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors	i	1	
PI3K	PI3KCG	5294	GSK2126458	PI3K Inhibitor GSK2126458	GSK2126458	25167777	N/A	inhibitor	pan-PI3K inhibitor	NCT01248858	Advanced Cancer Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.	I	1	
PI3K	PI3KCG	5294	ZSTK474	N/A	ZSTK474	11647372	N/A	inhibitor	pan-PI3K inhibitor	NCT01280487	Advanced cancer A Safety Study of Oral ZSTK474 in Patients With Cancer	I	1	
PI3K	PI3KCG	5294	BEZ235	NYP-BEZ235	NVP-BEZ237	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01343498	Advanced Cancer Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors	I	1	
PI3K	PI3KCG	5294	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-589	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCG	5294	PF-05212384, PF-04691502	PI3K/mTOR Kinase Inhibitor PF-04691502, PKI-587	PKI-593	44516953	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
PI3K	PI3KCG	5294	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01363232	NRAS, KRAS, or BRAF mutant advanced cancer A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors	I	1	
PI3K	PI3KCG	5294	DS-7423	N/A	N/A	N/A	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01364844	Advanced cancer Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors	I	1	
PI3K	PI3KCG	5294	SAR245409	XL765, PI3K/mTOR Dual Kinase Inhibitor XL765	XL765	49867926	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01390818	Adv cancer with mutation in PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ, GNA11 Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors	I	1	
PI3K	PI3KCG	5294	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01411410	Advanced solid tumors A Phase 1 Study of BAY80-6946 (Phosphatidylinositol 3?-Kinase Inhibitor) in Combination With Paclitaxel in Subjects With Advanced Solid Malignancy	I	1	
PI3K	PI3KCG	5294	SAR245408	XL147	XL147	1893730	N/A	inhibitor	pan-PI3K inhibitor	NCT01436565	Advanced Cancer A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers	I	1	
PI3K	PI3KCG	5294	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
PI3K	PI3KCG	5294	BEZ235	NYP-BEZ235	NVP-BEZ237	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01482156	Advanced Cancer Dose Finding Study of RAD001 (Everolimus, Afinitor) in Combination With BEZ235 in Patients With Advanced Solid Tumors	I	1	
PI3K	PI3KCG	5294	BEZ235	NYP-BEZ235	NVP-BEZ241	11977753	N/A	inhibitor	PI3K/mTOR inhibitor	NCT01508104	Advanced Cancer Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors	I	1	
PI3K	PI3KCG	5294	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01623349	Recurrent ovarian cancer Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer	I	1	
PI3K	PI3KCG	5294	P7170	PI3K/mTOR/ALK-1/DNA-PK inhibitor P7170	N/A	N/A	N/A	inhibitor	PI3K/mTOR/ALK-1/DNA-PK inhibitor	NCT01762410	Advanced Refractory Solid Tumors An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.	I	1	
PI3K	PI3KCG	5294	BAY 80-6946	N/A	BCP9000383	N/A	144115686	inhibitor	pan-PI3K inhibitor	NCT01392521	Advanced Cancer Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer	Ib	1	
PI3K	PI3KCG	5294	BKM120	NVP-BKM120	BKM120	16654980	N/A	inhibitor	pan-PI3K inhibitor	NCT01550380	Advanced ovarian cancer w/ P13K pathway activation A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers	II	1	
AMPK	PRKAA1	5562	Metformin	Fortamet, Glucophage, Glumetza, Riomet	Metformin hydrochloride	14219	N/A	activator	AMP-activated protein kinase (AMPK) activator	NCT01529593	Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers	I	1	
AMPK	PRKAA1	5562	Metformin	Fortamet, Glucophage, Glumetza, Riomet	Metformin hydrochloride	14219	N/A	activator	AMP-activated protein kinase (AMPK) activator	NCT01579812	Advanced ovarian cancer A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	II	1	
AMPK	PRKAA2	5563	Metformin	Fortamet, Glucophage, Glumetza, Riomet	Metformin hydrochloride	14219	N/A	activator	AMP-activated protein kinase (AMPK) activator	NCT01529593	Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers	I	1	
AMPK	PRKAA2	5563	Metformin	Fortamet, Glucophage, Glumetza, Riomet	Metformin hydrochloride	14219	N/A	activator	AMP-activated protein kinase (AMPK) activator	NCT01579812	Advanced ovarian cancer A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	II	1	
AMPK	PRKAB1	5564	Metformin	Fortamet, Glucophage, Glumetza, Riomet	Metformin hydrochloride	14219	N/A	activator	AMP-activated protein kinase (AMPK) activator	NCT01529593	Advanced cancers Phase I Study of Temsirolimus in Combination With Metformin in Patients With Advanced Cancers	I	1	
AMPK	PRKAB1	5564	Metformin	Fortamet, Glucophage, Glumetza, Riomet	Metformin hydrochloride	14219	N/A	activator	AMP-activated protein kinase (AMPK) activator	NCT01579812	Advanced ovarian cancer A Phase II Evaluation of Metformin, Targeting Cancer Stem Cells for the Prevention of Relapse in Patients With Stage IIC/III/IV Ovarian, Fallopian Tube, and Primary Peritoneal Cancer	II	1	
Focal Adhesion Kinase (FAK)	PTK2	5747	VS-6063	N/A	N/A	N/A	N/A	inhibitor	FAK inhibitor	NCT01778803	Adv or refractory ovarian cancer A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer	I	1	
RET	RET	5976	Vandetanib	AZD6474, Zactima, ZD6474	Vandetanib	3081361	N/A	inhibitor	VEGFR, EGFR, and RET inhibitor	NCT01582191	Advanced cancers A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer	I	1	
RET	RET	5976	Dovitinib	RTK inhibitor TKI258	Dovitinib	9886808	N/A	inhibitor	Multi-targeted RTK inhibitor	NCT01831726	Advanced Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	I	1	
RFC-1	RFC1	5981	Pralatrexate	Folotyn, PDX	Pralatrexate	148121	N/A	inhibitor	RFC-1 targeted DHFR inhibitor	NCT01188876	Platinum sensitive relapsed ovarian cancer Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer	I/II	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01455532	Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors	I	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01624493	Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse	I/II	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01663857	Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer	I/II	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01131039	Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	II	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01296035	Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.	II	1	
Ribonucleotide reductase	RRM1	6240	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01455532	Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors	I	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01624493	Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse	I/II	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01663857	Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer	I/II	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01131039	Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	II	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01296035	Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.	II	1	
Ribonucleotide reductase	RRM2	6241	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01455532	Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors	I	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01460537	Advanced Cancer Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor BAY80-6946 With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer	I	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01624493	Relapsed ovarian cancer, platinum sensitive Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse	I/II	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01663857	Platinum sensitive ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer	I/II	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01131039	Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	II	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01296035	Metastatic, advanced, or recurrent platinum-resistant epithelial ovarian, primary peritoneal or fallopian tube cancer A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.	II	1	
Ribonucleotide reductase	RRM2B	50484	Gemcitabine	Gemzar	gemcitabine	60750	N/A	inhibitor	Ribonucleotide reductase and DNA synthesis inhibitor	NCT01610206	Recurrent ovarian cancer A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
TROP2 [EGP-1 (epithelial glycoprotein-1)]	TACSTD2	4070	IMMU-132	anti-TROP-2 Antibody-Drug Conjugate IMMU-132, hrS7-SN38 antibody drug conjugate	N/A	N/A	N/A	inhibitor	TROP2-targeted TOPO I inhibitor	NCT01631552	Metastatic ovarian cancer A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer	I	1	
Tie-2	TEK	7010	Cabozantanib	Cabozantinib, Cometriq	Cabozantinib	25102847	N/A	inhibitor	RTK, HGFR, VEGFR2, KIT, Flt3, and Tie-2 inhibitor	NCT01716715	Recurrent epithelial ovarian cancer A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER	II	1	
TLR8	TLR8	51311	VTX-2337	TLR8 Agonist VTX-2337, Toll-like Receptor 8 Agonist VTX-2337	SureCN254984	16049404	N/A	immunostimulator	immunostimulator	NCT01666444	Platinum resistant recurrent epithelial ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With doxil (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	II	1	
TNF-alpha	TNF	7124	Lenalidomide	CC-5013, IMID-1, Revlimid	lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	1	
TNF-alpha	TNF	7124	Lenalidomide	CC-5013, IMID-1, Revlimid	lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
RANKL	TNFSF11	8600	Denosumab	N/A	Denosumab	N/A	135285955	antagonist	RANKL antagonist	NCT01624766	Advanced cancers A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies	I	1	
TOPO I	TOP1	7150	Irinotecan	Campothecin-11, Campto, Camptosar	irinotecan	60838	N/A	inhibitor	TOPO I inhibitor	NCT01347866	Advanced Cancer Study Of PI3K/mTOR Inhibitors In Combination With A MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer	I	1	
TOPO I	TOP1	7150	IMMU-132	anti-TROP-2 Antibody-Drug Conjugate IMMU-132, hrS7-SN38 antibody drug conjugate	N/A	N/A	N/A	inhibitor	TROP2-targeted TOPO I inhibitor	NCT01631552	Metastatic ovarian cancer A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer	I	1	
TOPO I	TOP1	7150	Topotecan	Hycamptamine, Hycamtin, TOPO	topotecan	60700	N/A	inhibitor	TOPO I inhibitor	NCT01012817	Platinum-refractory or recurrent (< 1yr after Pt treatment) ovarian epithelial or primary peritoneal cancer A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy	I/II	1	
TOPO I	TOP1	7150	Topotecan	Hycamptamine, Hycamtin, TOPO	topotecan	60700	N/A	inhibitor	TOPO I inhibitor	NCT01696032	Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer	I/II	1	
TOPO I	TOP1	7150	CRLX101	camptothecin-polymer conjugate IT-101, cyclodextrin-based polymer-camptothecin CRLX101, IT-101	Camptothecin	24360	N/A	HIF-1alpha	dual inhibitor of topoisomerase 1 and HIF-1alpha	NCT01652079	Recurrent epithelial cancer A Phase II, 2-stage Trial of CRLX101-202 in Recurrent Ovarian, Tubal and Peritoneal Cancer	II	1	
TOPO I	TOP1	7150	Irinotecan	Campothecin-11, Campto, Camptosar	irinotecan	60838	N/A	inhibitor	TOPO I inhibitor	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	1	
TOPO I	TOP1	7150	Topotecan	Hycamptamine, Hycamtin, TOPO	topotecan	60700	N/A	inhibitor	TOPO I inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01145430	Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER	I	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01281514	Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE	I	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01455532	Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors	I	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01459380	Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer	I	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01489371	Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	I	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01715168	Recurrent ovarian cancer A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy	I	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01815294	Advanced solid tumors A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.	I	1	
TOPO II	TOP2A	7153	Idronoxil	Phenoxodiol	Dehydroequol	219100	N/A	inhibitor	Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01696032	Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer	I/II	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT00982631	Advanced or Recurrent Ovarian Cancer A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer	Ib	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT00003135	Metastatic ovarian cancer Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer	II	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01666444	Platinum resistant recurrent epithelial ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With doxil (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	II	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01170650	primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED)	III	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01281254	Recurrent ovarian cancer A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	III	1	
TOPO II	TOP2A	7153	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01145430	Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PHASE I STUDY OF ABT-888, PARP INHIBITOR, AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) IN RECURRENT GYNECOLOGIC CANCER AND BREAST CANCER	I	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01281514	Platinum-sensitive ovarian cancer at first relapse PHASE I STUDY OF CARBOPLATIN, PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND EVEROLIMUS IN PATIENTS WITH PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER IN FIRST RELAPSE	I	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01455532	Advanced solid tumors A Phase 1/1b Dose Escalation Study Evaluating Iniparib (BSI201/SAR240550) as a Single Agent and in Combination With Chemotherapeutic Regimens in Patients With Solid Tumors	I	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01459380	Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer A Phase I Trial of Doxil ), Carboplatin and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer	I	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01489371	Recurrent epithelial ovarian cancer A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With doxil (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	I	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01715168	Recurrent ovarian cancer A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy	I	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01815294	Advanced solid tumors A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.	I	1	
TOPO II	TOP2B	7155	Idronoxil	Phenoxodiol	Dehydroequol	219100	N/A	inhibitor	Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01485874	Platinum-resistant or refractory ovarian cancer A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149	I/II	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01696032	Ovarian Cancer A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer	I/II	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT00982631	Advanced or Recurrent Ovarian Cancer A Phase Ib Study of Combination of Temsirolimus (Torisel) and Pegylated Liposomal Doxorubicin (PLD, Doxil/ Caelyx) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer	Ib	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT00003135	Metastatic ovarian cancer Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer	II	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01666444	Platinum resistant recurrent epithelial ovarian cancer A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With doxil (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	II	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01170650	primary or secondary platinum-resistant ovarian cancer Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil (PROCEED)	III	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01281254	Recurrent ovarian cancer A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	III	1	
TOPO II	TOP2B	7155	Doxil	Dox-SL, Evacet, LipoDox, liposomal doxorubicin, Pegylated Liposomal Doxorubicin Hydrochloride	doxorubicin	31703	N/A	inhibitor	DNA intercalator and TOPO II inhibitor	NCT01849874	Recurrent low grade serous ovarian , fallopian tube, peritoneal cancer A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer	III	1	
TRPV6 calcium channel	TRPV6	55503	SOR-C13	N/A	N/A	N/A	N/A	inhibitor	peptide TRPV6 inhibitor	NCT01578564	Advanced ovarian cancer Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel	I	1	
Thymidylate synthase	TYMS	7298	Fluorouracil	5-fluorouracil, 5-Fluracil, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Flurox, FU, Ribofluor, Timazin	Fluorouracil	3385	N/A	inhibitor	RNA processing inhibitor and thymidylate synthase inhibitor	NCT00610948	Advanced solid tumors A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies	I	1	
Thymidylate synthase	TYMS	7298	Pemetrexed	Alimta, Pemetrexed disodium	MLS003106905	N/A	446556	inhibitor	DHFR and Thymidylate synthase inhibitor	NCT01172028	Advanced, recurrent solid tumor Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors	I	1	
Thymidylate synthase	TYMS	7298	Capecitabine	CAPE, Xeloda	CAPECITABINE	60953	N/A	inhibitor	RNA processing inhibitor and thymidylate synthase inhibitor	NCT01233505	Metastatic mucinous ovarian cancer and/or BRCA1/2 mutant Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	I	1	
Thymidylate synthase	TYMS	7298	Pemetrexed	Alimta, Pemetrexed disodium	MLS003106905	N/A	446556	inhibitor	DHFR and Thymidylate synthase inhibitor	NCT01567384	Advanced Cancer A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies	I	1	
Thymidylate synthase	TYMS	7298	Floxuridine	5-FUDR, WR-138720	floxuridine	5790	N/A	inhibitor	RNA and DNA synthesis inhibitor	NCT01749397	Recurrent (metastatic) epithelial ovarian cancer A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers	I	1	
Thymidylate synthase	TYMS	7298	Fluorouracil	5-fluorouracil, 5-Fluracil, AccuSite, Actino-Hermal, Adrucil, Arumel, Cytosafe, Efudex, Efurix, Fiverocil, Fluoro Uracil, Fluoroplex, Fluouracil, Flurablastin, Flurox, FU, Ribofluor, Timazin	5-Fluorouracil	3385	N/A	inhibitor	RNA processing inhibitor and thymidylate synthase inhibitor	NCT00003135	Metastatic ovarian cancer Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer	II	1	
Thymidylate synthase	TYMS	7298	Pemetrexed	Alimta, Pemetrexed disodium	MLS003106905	N/A	446556	inhibitor	DHFR and Thymidylate synthase inhibitor	NCT01001910	Platinum sensitive relapsed ovarian cancer Pemetrexed and Carboplatin in Recurrent Platinum Sensitive Ovarian Cancer	II	1	
Thymidylate synthase	TYMS	7298	Capecitabine	CAPE, Xeloda	CAPECITABINE	60953	N/A	inhibitor	RNA processing inhibitor and thymidylate synthase inhibitor	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	1	
VEGF	VEGFA	7422	Lenalidomide, Bevacizumab	anti-VEGF monoclonal antibody, Avastin, CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	antagonist	Anti-angiogenic., VEGF antagonist	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
VEGF	VEGFA	7422	Lenalidomide	CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01831089	Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors	I	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01010126	Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor	II	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01031381	Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV)	II	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01097746	Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer	II	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01131039	Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	II	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01305213	Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT00565851	Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	III	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01167712	Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	III	1	
VEGF	VEGFA	7422	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01239732	Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma	III	1	
VEGF	VEGFB	7423	Lenalidomide, Bevacizumab	anti-VEGF monoclonal antibody, Avastin, CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	antagonist	Anti-angiogenic., VEGF antagonist	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
VEGF	VEGFB	7423	Lenalidomide	CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01831089	Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors	I	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01010126	Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor	II	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01031381	Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV)	II	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01097746	Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer	II	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01131039	Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	II	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01305213	Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT00565851	Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	III	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01167712	Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	III	1	
VEGF	VEGFB	7423	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01239732	Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma	III	1	
VEGF	VEGFC	7424	Lenalidomide, Bevacizumab	anti-VEGF monoclonal antibody, Avastin, CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	antagonist	Anti-angiogenic., VEGF antagonist	NCT01146795	Stage III, IV ovarian epithelial cancer Neoadjuvant Therapy for Ovarian Cancer	0	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT00989651	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	I	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01248949	Advanced Recurrent Ovarian Tumors Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI3617 as a Single-Agent or in Combination Therapy in Adult Subjects With Advanced Solid Tumors	I	1	
VEGF	VEGFC	7424	Lenalidomide	CC-5013, IMID-1, Revlimid	Lenalidomide	216326	N/A	Anti-angiogenic.	Anti-angiogenic.	NCT01352962	Advanced solid tumors A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors	I	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01831089	Advanced solid tumors Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors	I	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01010126	Locally advanced, recurrent, metastatic, or progressive endometrial cancer, ovarian epithelial cancer, liver cancer, islet cell cancer, or carcinoid tumor. Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor	II	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01031381	Recurrent epithelial ovarian carcinoma Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer (RADBEV)	II	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01097746	Newly diagnosed stage III, IV ovarian epithelial cancer First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer	II	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01131039	Platinum-Resistant Recurrent Ovarian Cancer Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer	II	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01305213	Platinum sensitive recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma A Randomized Phase II Evaluation of Single-Agent Bevacizumab (IND #7921) (NSC #704865) and Combination Bevacizumab With Fosbretabulin Tromethamine (CA4P) (NSC #752293) in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	II	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT00565851	Recurrent ovarian epithelial cancer Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	III	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01081262	Newly diagnosed ovarian cancer (before chemotherapy), diagnosed stage II, stage III, or stage IV or recurrent stage I ovarian cancer Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer	III	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01167712	Stage III, IV ovarian epithelial cancer Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	III	1	
VEGF	VEGFC	7424	Bevacizumab	anti-VEGF monoclonal antibody, Avastin	Bevacizumab	N/A	50067187	antagonist	VEGF antagonist	NCT01239732	Newly diagnosed advanced ovarian cncer Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma	III	1	
WEE1	WEE1	7465	MK1775	N/A	MK 1775	24856436	N/A	inhibitor	WEE1 inhibitor	NCT01357161	Platinum-sensitive p53 mutant ovarian cancer A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer	II	1	
XIAP	XIAP	331	Idronoxil	Phenoxodiol	Dehydroequol	219100	N/A	inhibitor	Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	1	
Caspases	XIAP	331	Idronoxil	Phenoxodiol	phenoxodiol	219100	N/A	inhibitor	Caspase activator, XIAP inhibitor, FLIP suppressor, and TOPO II inhibitor	NCT00303888	Platinum-sensitive, recurrent ovarian epithelial cancer Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer	I/II	1	
